Company / Current Liabilities
BIOCRYST PHARMACEUTICALS INC Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$196.1M
FY2025
5-year range
$103.7M / $196.1M
FY2021-FY2025
Trend
+22.2%
vs FY2024
Sector context
#60 of 213
Health Care
What the data says
At $196M, BIOCRYST PHARMACEUTICALS INC's current liabilities ranks #154 of 213 in the Health Care sector. Current Liabilities has increased for 4 consecutive years, from $104M in FY2021 to $196M in FY2025.
Based on SEC 10-K filings.
$196M in FY2025 with a 5-year CAGR of +13.2%.
Increased from $150M to $196M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +22.9%
- 5-Year CAGR
- +13.2%
- 10-Year CAGR
- -
Sector benchmark
#154 of 213 in Health CareTop 72% of 213This company $196.1M Sector average $1.6B
▼
-87.7% below sector average
Key checks
Key Insights
- BIOCRYST PHARMACEUTICALS INC's current liabilities has grown for 4 consecutive years.
- 5-year CAGR of +13.2%, indicating consistent growth.
- In FY2025, current liabilities increased 22.2% year-over-year.
- Ranks #60 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $196.1M | +22.2% |
| FY2024 | $160.4M | +6.9% |
| FY2023 | $150.0M | +42.1% |
| FY2022 | $105.5M | +1.7% |
| FY2021 | $103.7M | -1.8% |
| FY2020 | $105.7M | +14.4% |
| FY2019 | $92.3M | +32.9% |
| FY2018 | $69.5M | -7.2% |
| FY2017 | $74.8M | +37.7% |
| FY2016 | $54.4M | -12.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026